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ABSTRACT
Introduction: An investigation of whether
treatment of asymptomatic carriers of
Plasmodium falciparum with artemether–
lumefantrine (AL), in addition to the routine
treatment of symptomatic cases with AL, could
improve the prevalence of anemia in 18 villages
in Burkina Faso.
Methods: This was a single-center, controlled,
parallel, cluster-randomized study to evaluate
the effect of systematic treatment of
P. falciparum asymptomatic carriers at a
community level on hemoglobin (Hb) levels
and anemic status of children (\5 years) and
adults during four screening campaigns carried
out over a 12-month period, compared with
no treatment of asymptomatic carriers.
Results: The change in Hb level in all
asymptomatic carriers aged [6 months from
Day 1 to Day 28 of the first campaign was
?0.53 g/dl (from 11.81 to 12.33 g/dl) in the
intervention arm vs. -0.21 g/dl (from 12.06 to
11.86 g/dl) in the control arm (P\0.001).
During the same period, the proportion of
asymptomatic carriers aged [6 months to
\5 years with anemia in the intervention arm
decreased by 31.1% (from 75.7% to 44.6%),
compared with a decrease of 4.7% (from 76.3%
to 71.6%) in the control arm. Over 12 months,
the proportion of asymptomatic carriers with
anemia (mild, moderate, or severe) was reduced
in both arms.
Conclusion: Systematic screening and
treatment of asymptomatic carriers of
P. falciparum with AL at the community level
can reduce the prevalence of anemia in children
in the short term (28 days), although the effect
was not maintained at 12 months.
ClinicalTrials.gov #NCT01256658.
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INTRODUCTION
Recent application of malaria control strategies
has succeeded in reducing the malaria burden
in endemic regions [1–5], yet malarial anemia
remains a major cause of morbidity and
mortality [6, 7]. Plasmodium falciparum malaria
in Kenyan children was reported to account for
up to 75% of anemia-associated deaths and 9%
of all deaths [7]. Furthermore, children with
severe malarial anemia had a mortality rate of
8.6%, compared with 3.6% in children with
severe anemia due to other causes [7].
Malarial anemia is well known as a major
complication of symptomatic parasitemia. Less
well known is that it is also significantly
associated with low-density asymptomatic
parasitemia in children [8, 9]. This, coupled
with the fact that a large proportion (dependant
on factors such as population age, natural
immunity, and transmission rate) of infections
in endemic areas are asymptomatic [10–14],
means that the potential to further reduce
the burden of malarial anemia through
the treatment of asymptomatic carriers is
promising.
It is already known that interventions
that reduce malaria transmission, such as
insecticide-treated nets and chemoprophylaxis,
can improve hemoglobin (Hb) levels in children
[15–17], and that treatment of asymptomatic
children can improve their cognitive ability,
possibly as a result of raised Hb levels [18].
However, little is known about the effect of
community-level treatment of asymptomatic
carriers on Hb levels. Reducing malaria
transmission within a population through the
systematic screening and treatment of
asymptomatic persons could potentially
improve Hb levels.
This cluster-randomized trial of 18 villages in
Sapone´, Burkina Faso, investigated whether
systematic screening and treatment of
asymptomatic carriers of P. falciparum with
artemether–lumefantrine (AL) during three
community screening campaigns (Campaigns
1–3) could reduce the burden of malaria and
whether this intervention, in addition to the
routine treatment of symptomatic P. falciparum
carriers with AL, could improve Hb levels and
reduce the prevalence of anemia. Primary
outcomes were the number of microscopy-
confirmed cases of symptomatic malaria with
a parasite density [5,000/ll per person-year in
infants and children \5 years of age and the
change in Hb level from Day 1 to Day 28 of
Campaign 1 in asymptomatic carriers
[6 months of age, between the intervention
and control arm. Results from the first primary
outcome showed that systematic screening
with a rapid diagnostic test (RDT) and
treatment of asymptomatic carriers did not
reduce clinical malaria incidence in the
subsequent transmission season. The number
of symptomatic malaria episodes at 12 months
(microscopy-confirmed symptomatic malaria
episodes including fever and a parasite density
[5,000/ll) per person-year in infants and
children aged \5 years was 1.69 (SD ± 0.436)
in the intervention arm vs. 1.60 (SD ± 0.526) in
the control arm (P = 0.3482). The number of
symptomatic malaria episodes of any parasite
density per person-year in infants and children
aged \5 years was also not significantly
different between the two arms [19]. Herein,
the authors report on the changes in Hb levels
and prevalence of anemia in asymptomatic
carriers and at community level. AL has
demonstrated high cure rates with a good
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safety and tolerability profile in P. falciparum
malaria in many different populations around
the world, consistently achieving 28-day
polymerase chain reaction (PCR)-corrected cure
rates of [95%, and rapidly clearing parasitemia
and fever [20]. AL has been included on the
World Health Organization (WHO) Model List
of Essential Medicines since March 2002 [21].
MATERIALS AND METHODS
Full study methodology has previously been
published by Tiono et al. [19].
Study Design
This was a single-center, controlled, parallel,
cluster-randomized study that evaluated the
effect of systematic treatment of P. falciparum
asymptomatic carriers at a community level on
Hb levels and anemic status of children
(\5 years) and adults over a 12-month period,
compared with no treatment of asymptomatic
carriers. The study was carried out between
November 2010 and February 2012. Clusters
were randomized and assigned in a 1:1 ratio to
the control or intervention arm.
During the implementation phase of the
study, intervention and control village
inhabitants participated in Campaigns 1–3
that took place approximately 1 month apart,
before the start of the rainy season. Campaign 4
was conducted after the rainy season had ended
to mark the end of the study at 12 months
(Fig. 1) [19]. At each campaign, finger-prick
blood samples were taken from the entire
study population in the intervention arm and
a randomly selected 40% in the control arm for
screening for P. falciparum asexual forms and
gametocytes, and assessment of Hb level (only
performed during Campaigns 1 and 4). In the
intervention arm, the population was screened
using RDT (First Response Malaria Ag, Premier
Medical Corp Ltd., Nani-Daman, India).
Subjects with a positive RDT on Day 1 of
Campaign 1 had blood samples taken for
microscopy and Hb level assessment on Day
28 of Campaign 1. Subjects in the control arm
were not screened by RDT—microscopy alone
with delayed reading was used to ensure that
study personnel and screened subjects remained
unaware of a subject’s status.
Study Population
The study took place in the health district of
Sapone´, about 50 km south of Ouagadougou in
Burkina Faso, an area with marked seasonal
(June to November) P. falciparum malaria
transmission [22]. Eighteen clusters, each
comprising of one village, were selected for
inclusion in the trial. All inhabitants of each
cluster were invited to participate in the trial.
Written informed consent was received from all
study participants or their legal guardians.
Interventions
All members of the study population who were
diagnosed by RDT as asymptomatic carriers in
the intervention arm, or who were diagnosed
with symptomatic malaria confirmed by RDT in
the intervention and control arms, received AL.
Subjects with contraindications for AL received
alternative treatment according to national
guidelines. All households received long-lasting
insecticide-impregnated bednets (LLINs; Olyset
nets [Sumitomo Chemical Co, Ltd, Tokyo,
Japan]) prior to the implementation phase.
Monitoring
Throughout the study, community healthcare
workers visited households to check and
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document treatment adherence of asymptomatic
carriers and those with symptomatic malaria
through the use of a drug accountability log and
tablet counts. The use of LLINs was checked at
the home visits conducted at least every
two months, and additional training was
provided when required. Adverse events and
serious adverse events were also recorded, as
previously described by Tiono et al. [19].
Study Medication
All individuals with a positive RDT in the
intervention arm received AL/AL dispersible
(20 mg artemether and 120 mg lumefantrine),
adjusted according to body weight, twice a day
for three consecutive days. The first dose was
supervised. Individuals with contraindications
to AL and AL dispersible, or any female who was
either in the first trimester of pregnancy or of
childbearing potential who did not take the
urine pregnancy test, received alternative
treatment. Subjects with Hb \5 g/dl on Day 1
of Campaign 1 were referred to the local
healthcare facility where hematinics were
given. Full details have previously been
published by Tiono et al. [19].
Laboratory Methods
Hb level was measured using the HemoCue Hb
201? rapid test (A¨ngelholm, Sweden) using blood
collected by finger-prick on Day 1 and Day
28 of Campaign 1 and on Day 1 of Campaign 4.
Statistical Analysis
Data analysis, performed with SAS Software
(Version 9.3; SAS Institute, Cary, NC, USA) of
the SAS System for Unix, followed a cluster-level
Fig. 1 Single-center, controlled, parallel, cluster-randomized, 12-month prospective study. qRT-PCR real-time quantitative
reverse transcription polymerase chain reaction, RDT rapid diagnostic test
50 Infect Dis Ther (2013) 2:47–58
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approach where a summary measure per cluster
was used. A one-sided t test of equal means was
conducted to a significance level of 0.05 for all
outcome measures. The distribution of Hb levels
at different time points (Days 1 and 28 of
Campaign 1, and Day 1 of Campaign 4) was
presented as a box plot.
Outcome Measures and Endpoints
In order to quantify a potential direct benefit on
Hb levels associated with AL treatment in
asymptomatic carriers, outcomes were assessed
in subjects with microscopy-confirmed
asymptomatic malaria detected on Day 1 of
Campaign 1. Separate outcomes aimed at
assessing the potential improvement of
community-wide Hb levels were also conducted.
Outcomes in Microscopy-Confirmed
Asymptomatic Carriers
The first primary endpoint was the number of
RDT and microscopy-confirmed cases of
symptomatic malaria with a parasite density
[5,000/ll per person-year in infants and
children \5 years of age in the intervention
compared with the control arm. The second
primary endpoint was the change in Hb level
from Day 1 to Day 28 of Campaign 1 in
asymptomatic carriers [6 months of age,
between the intervention and control arm.
Secondary endpoints were the proportion of
all asymptomatic carriers aged [6 months to
\5 years who increased their Hb level by at least
0.5 g/dl during Campaign 1 and the change in
anemic status over time (from Day 1 to Day 28
of Campaign 1 and to Day 1 of Campaign 4) in
asymptomatic carriers aged [6 months up to
\5 years. Anemic status was defined as severe
anemia = Hb \5 g/dl, moderate anemia = Hb 5
to \8 g/dl, mild anemia = Hb 8 to \11 g/dl, no
anemia = Hb C11 g/dl.
Outcomes in All Subjects (Community Level)
Secondary endpoints were the change in Hb
levels from Campaign 1 to Campaign 4 in
children aged [6 months to \5 years, 5–9 years
and 10–14 years, as well as in subjects aged
C15 years. The distribution of Hb levels at
different time points (Days 1 and 28 of
Campaign 1, and Day 1 of Campaign 4), for
the different age groups was also assessed.
Ethics Section
The protocol and the informed consent form were
reviewed and approved by the Centre National de
Recherche et de Formation sur le Paludisme
Institutional Review Board and by the National
Ethical Committee for Health Research of Burkina
Faso. Prior to study initiation, a community
meeting was held in each of the selected clusters
to discuss the study with the community. The
freedom of each individual household and each
householdmember todecideonparticipation was
discussed to minimize the potential influence of
key opinion leaders in each cluster. Individual
informed consent was obtained from each
participant during a visit to the household
before any study procedure. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1975, as revised in 2000. Informed consent was
obtained from all participants included in the
study.
RESULTS
A total of 6,817 persons in the intervention arm
and 7,258 persons in the control arm were
enrolled, and 86.5% (5,897) of the persons in
the intervention arm and 89.7% (6,510) of the
persons in the control arm completed the study
Infect Dis Ther (2013) 2:47–58 51
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(Table 1). Loss to follow-up (the most common
reason for discontinuation) was slightly more
common in the intervention arm (12.3%) than
in the control arm (9.1%). Full details were
published by Tiono et al. [19].
The intervention and control arms were
comparable in terms of demographic
characteristics with the exception of ethnicity:
90.6% of the intervention arm was Mossi and
8.7% was Fulani, while the control was 95.7%
Mossi and 3.8% Fulani.
Outcomes in Microscopy-Confirmed
Asymptomatic Carriers
There was a significant difference in the change
in Hb levels from Day 1 to Day 28 of Campaign
1 for all asymptomatic carriers aged [6 months
(primary endpoint). The change in Hb level was
?0.53 g/dl (from 11.81 to 12.33 g/dl) in the
intervention arm vs. -0.21 g/dl (from 12.06 to
11.86 g/dl) in the control arm (P\0.001).
Following this trend, significantly more
asymptomatic carriers aged [6 months to
\5 years raised their Hb level by C0.5, C1.0,
C1.5, and C2.0 g/dl from Day 1 to Day 28
(Campaign 1) in the intervention arm than in
the control arm (Fig. 2).
Larger increases in Hb were seen in the
intervention arm relative to the control arm in
subjects with medium and high baseline
parasite densities as compared with those with
low densities (Fig. 3).
A more substantial improvement in the
proportion of asymptomatic carriers aged
[6 months to \5 years with anemia (mild,
moderate or severe) was seen in the
intervention arm than in the control arm over
the first 28 days (Day 1 to Day 28 of Campaign
1). The proportion of asymptomatic carriers
with anemia in the intervention arm decreased
by 31.1% (from 75.7% to 44.6%), compared
with a decrease of 4.7% (from 76.3% to 71.6%)
in the control arm (Fig. 4).
Over 12 months, the proportion of
asymptomatic carriers aged [6 months up to
\5 years with anemia (mild, moderate or
severe) decreased in both arms (Day 1 of
Campaign 1 to Campaign 4). The proportion
in the intervention arm decreased by 29.9%
(from 75.7% to 45.8%), compared with a
decrease of 36.8% (from 76.3% to 39.5%) in
the control arm (Fig. 4). However, there was no
marked difference in the reduction of






Number enrolled 6,817 7,258
Born after cluster
initiation (%)
151 (2.2) 128 (1.8)
Immigrant during
the study (%)
349 (5.1) 207 (2.9)
Persons completed (%) 5,897 (86.5) 6,510 (89.7)
Male sex (%) 46.4 47.4
Age at Campaign 1 Day 1
Mean (years) 24.1 23.4
Age group (%)
B6 months 2.1 1.5
[6 months to\5 years 14.9 14.2
5–9 years 15.8 16.6
10–14 years 15.5 15.3
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asymptomatic carriers with anemia between
each arm over this 12-month period.
Outcomes in All Subjects (Community
Level)
There was no significant difference in the
increase in Hb from Campaign 1 to 4 in
subjects aged [6 months to \5 years between
the two arms. The change in Hb level was
?0.76 g/dl (from 10.24 to 10.99 g/dl) in the
intervention arm vs. ?1.08 g/dl (from 10.04 to
11.13 g/dl) in the control arm (P = 0.9318).
The difference between the increase in Hb
from Campaign 1 to 4 in subjects aged 5–9,
10–14, and C15 years in the two arms was not
Fig. 2 Proportion of all asymptomatic carriers aged[6 months to\5 years with an increase in hemoglobin (Hb) level from
Day 1 to Day 28 of Campaign 1. ACs asymptomatic carriers
Fig. 3 Proportion of all asymptomatic carriers aged
[6 months to \5 years with an increase in hemoglobin
(Hb) level from Day 1 to Day 28 of Campaign 1, stratiﬁed
by baseline parasite density. ACs asymptomatic carriers.
*Low \1,000/ll, Medium (Med) 1,000–4,999/ll, High
C5,000/ll
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significant. Hb levels at Campaign 4 in these age
groups were similar to Hb levels in populations
without endemic malaria, and there was a trend
of increasing Hb level with increasing age:
children aged 5–9 years had a mean Hb of
11.97 vs. 12.13 g/dl (intervention vs. control
arms), and children aged 10–14 years had a
mean Hb of 12.58 vs. 12.72 g/dl, while study
participants aged C15 years had a mean Hb of
13.25 vs. 13.42 g/dl.
Distribution of Hb Levels (All Subjects)
Hb levels within both study arms were similarly
distributed on Days 1 and 28 of Campaign 1, and
on Day 1 of Campaign 4, with the majority of the
Hb levels falling within the outer limits. There was
little difference between the study arms in the
distribution of Hb levels on Day 1 and Day 28 of
Campaign 1 and on Day 1 of Campaign 4 (Fig. 5).
DISCUSSION
In this study, community screening and
targeted treatment of asymptomatic carriers of
P. falciparum malaria had a significant impact
on short-term (28 days) Hb levels in these
asymptomatic carriers, including significantly
improving Hb levels in all asymptomatic
carriers [6 months, and reducing the
incidence of anemia in asymptomatic carriers
aged [6 months to \5 years by over 30%.
However, more research is needed to
understand if this is a direct effect of AL
therapy. While it is known that AL has a
consistently high efficacy and safety in the
treatment of P. falciparum malaria [20], some
factors in this study, such as the concurrent
treatment of all symptomatic cases in both
arms, and the use of LLINs, may have
contributed to the improved Hb levels. It
should be noted that these short-term
improvements in Hb levels did correlate with
the reduction in carriage of asexual forms and
gametocytes seen in these asymptomatic
carriers after 28 days of AL therapy (there was
a significant reduction in asymptomatic and
gametocyte carriage from baseline to the
assessment at the beginning of Campaigns 2
and 3) [19]. Only 0.2% of patients in the
Fig. 4 Reduction in anemia in asymptomatic carriers aged[6 months up to\5 years over 28 days and 12 months
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intervention arm and none in control arm
required hematinic treatment (for Hb \5 g/dl
on Day 1 of Campaign 1), making it unlikely
that this intervention influenced the overall
Hb changes.
While the interventions in the study resulted
in a significantly greater increase in Hb in
asymptomatic carriers aged [6 months over
28 days in the intervention arm than in the
control arm, this improvement was not of a
sufficient magnitude to be considered clinically
meaningful. This was probably because the
mean baseline Hb level in both arms was
within the normal range (intervention:
11.81 g/dl; control 11.86 g/dl), making a large
increase in Hb unlikely. However, over these
28 days, it is encouraging that (a) a significantly
larger proportion of asymptomatic carriers aged
[6 months up to \5 years in the intervention
arm raised their Hb levels by C2.0 g/dl than in
the control arm (Fig. 2), and (b) the proportion
of these asymptomatic carriers with anemia in
the intervention arm decreased substantially
more than that in the control arm (31.1% vs.
4.7%; Fig. 4).
It is interesting to note that while the
reduction in anemia in asymptomatic carriers
was sustained in the intervention arm over
12 months, anemia was also reduced in the
control arm over this period. This suggests a
possible study effect owing to the availability of
AL for all confirmed cases of symptomatic
malaria and the provision of an LLIN to every
participant in the study. A recent study, which
examined the coverage of malaria control
interventions in Burkina Faso, reported that
59% of households in the study population
owned an insecticide-treated bednet (ITN) and
only 34% of children under 5 years of age with a
reported malaria case were treated with an
artemisinin-based combination therapy (ACT)
[23]. It is, therefore, possible that receipt of an
LLIN by every study participant increased the
use of ITNs in both study arms. A Cochrane
Review of the impact of medicated bednets
concluded that sleeping under one improved
Hb level in children by 1.7% packed cell volume
[24]. Additionally, the high level of general
medical attention and easy availability of a
high-quality ACT to treat confirmed malaria
cases throughout the duration of the study may
have contributed to a reduction in parasite levels
in both arms as compared with baseline [19].
While the impact of improved Hb levels on
quality of life is not known, it has previously
been shown that asymptomatic infection can
also affect cognitive performance, and that
treatment of asymptomatic malaria improves
children’s cognitive ability [18]. It has also
been shown, through fixed effects estimates,
Fig. 5 Distribution of hemoglobin (Hb) levels in all subjects on Day 1, Day 28, and at 12 months
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that asymptomatic malaria and the presence of
P. falciparum malaria parasites have a direct,
causal correlation with educational
achievement and cognitive performance in
primary school children [25]. Further research
is needed to understand the potential benefit
on quality of life of improving Hb levels
through treatment of asymptomatic carriers
with AL. This is particularly pertinent as
asymptomatic carriers tend not to seek
treatment yet may benefit from AL therapy.
Hb levels in the community (all subjects)
increased over 12 months, with no significant
difference between the intervention and control
arms in mean levels or distribution, and median
and 25th percentile Hb levels remained above
the defined limit for anemia at all times in both
arms. Again, the treatment of all symptomatic
cases, and the widespread use of LLINs in both
arms, could make it difficult to identify any
direct benefit on Hb levels due to the treatment
of asymptomatic carriers in the intervention
arm.
CONCLUSION
This study demonstrates that systematic
screening and treatment of asymptomatic
carriers of P. falciparum with AL at the
community level may improve Hb levels
and reduce the prevalence of anemia in
asymptomatic children over the short term.
Further research is needed to establish
whether these Hb improvements are linked
directly to the treatment of asymptomatic
carriers with AL and to quantify the clinical
significance of any treatment-related Hb
improvements. No longer-term (12 months)
Hb improvements in asymptomatic carriers,
or at a community level, were noted,
although these outcomes were possibly
influenced by confounding factors, such as
the treatment of all confirmed cases of
symptomatic malaria with AL and the
provision of an LLIN to every participant in
the study.
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